Literature DB >> 25115711

Mobile elements and chromosomal changes associated with MLS resistance phenotypes of invasive pneumococci recovered in the United States.

Paulina A Hawkins1, Sopio Chochua, Delois Jackson, Bernard Beall, Lesley McGee.   

Abstract

Pneumococcal macrolide resistance is usually expressed as one of two phenotypes: the M phenotype conferred by the mef gene or the MLSB phenotype caused by modification of ribosomal targets, most commonly mediated by an erm methylase. Target-site modification leading to antibiotic resistance can also occur due to sequence mutations within the 23S rRNA or the L4 and L22 riboproteins. We screened 4,535 invasive isolates resistant to erythromycin and 18 invasive isolates nonsusceptible to quinupristin-dalfopristin (Q-D) to deduce the potential mechanisms involved. Of 4,535 erythromycin-resistant isolates, 66.2% were polymerase chain reaction (PCR)-positive for mef alone, 17.8% for ermB alone, and 15.1% for both mef and ermB. Thirty-seven isolates (0.9%) were PCR negative for both determinants. Of these, 3 were positive for ermA (subclass ermTR) and 25 had chromosomal mutations. No chromosomal mutations (in 23S rRNA, rplD, or rplV) nor any of the macrolides/lincosamides/streptogramin (MLS) resistance genes screened for (ermT, ermA, cfr, lsaC, and vgaA) were found in the remaining nine isolates. Of 18 Q-D nonsusceptible isolates, 14 had chromosomal mutations and one carried both mef and ermB; no chromosomal mutations or other resistance genes were found in 3 isolates. Overall, we found 28 mutations, 13 of which have not been previously described in Streptococcus pneumoniae. The role of these mutations remains to be confirmed by transformation assays.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25115711      PMCID: PMC5735413          DOI: 10.1089/mdr.2014.0086

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  52 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.

Authors:  Ronald N Jones; David J Farrell; Ian Morrissey
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era.

Authors:  Robert E Gertz; Zhongya Li; Fabiana C Pimenta; Delois Jackson; Billie A Juni; Ruth Lynfield; James H Jorgensen; Maria da Gloria Carvalho; Bernard W Beall
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

4.  Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).

Authors:  A K Wierzbowski; K Nichol; N Laing; T Hisanaga; A Nikulin; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  J Antimicrob Chemother       Date:  2007-08-02       Impact factor: 5.790

5.  Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.

Authors:  David J Farrell; Keith P Klugman; Michael Pichichero
Journal:  Pediatr Infect Dis J       Date:  2007-02       Impact factor: 2.129

6.  Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.

Authors:  A Tait-Kamradt; T Davies; M Cronan; M R Jacobs; P C Appelbaum; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

7.  Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.

Authors:  David J Farrell; Thomas M File; Stephen G Jenkins
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

8.  Shifting genetic structure of invasive serotype 19A pneumococci in the United States.

Authors:  Bernard W Beall; Robert E Gertz; Rachel L Hulkower; Cynthia G Whitney; Matthew R Moore; Angela B Brueggemann
Journal:  J Infect Dis       Date:  2011-03-11       Impact factor: 5.226

9.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Mutations within the rplD Gene of Linezolid-Nonsusceptible Streptococcus pneumoniae Strains Isolated in the United States.

Authors:  W Dong; S Chochua; L McGee; D Jackson; K P Klugman; J E Vidal
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

View more
  9 in total

1.  Macrolones Are a Novel Class of Macrolide Antibiotics Active against Key Resistant Respiratory Pathogens In Vitro and In Vivo.

Authors:  Hana Čipčić Paljetak; Donatella Verbanac; Jasna Padovan; Miroslava Dominis-Kramarić; Željko Kelnerić; Mihaela Perić; Mihailo Banjanac; Gabrijela Ergović; Nerrisa Simon; John Broskey; David J Holmes; Vesna Eraković Haber
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

2.  Three critical regions of the erythromycin resistance methyltransferase, ErmE, are required for function supporting a model for the interaction of Erm family enzymes with substrate rRNA.

Authors:  Rory E Sharkey; Johnny B Herbert; Danielle A McGaha; Vy Nguyen; Allyn J Schoeffler; Jack A Dunkle
Journal:  RNA       Date:  2021-11-18       Impact factor: 4.942

Review 3.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

4.  Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan.

Authors:  M Kawaguchiya; N Urushibara; M S Aung; S Morimoto; M Ito; K Kudo; A Sumi; N Kobayashi
Journal:  New Microbes New Infect       Date:  2015-11-11

Review 5.  Macrolide Resistance in Streptococcus pneumoniae.

Authors:  Max R Schroeder; David S Stephens
Journal:  Front Cell Infect Microbiol       Date:  2016-09-21       Impact factor: 5.293

6.  Determination of Characteristics of Erythromycin Resistant Streptococcus pneumoniae with Preferred PCV Usage in Iran.

Authors:  Malihe Talebi; Azadeh Azadegan; Javad Sadeghi; Ali Ahmadi; Mostafa Ghanei; Mohammad Katouli; Parviz Owlia; Mohammad R Pourshafie
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

7.  Inducible Expression of both ermB and ermT Conferred High Macrolide Resistance in Streptococcus gallolyticus subsp. pasteurianus Isolates in China.

Authors:  Meixia Li; Chao Cai; Juan Chen; Changwei Cheng; Guofu Cheng; Xueying Hu; Cuiping Liu
Journal:  Int J Mol Sci       Date:  2016-09-22       Impact factor: 5.923

8.  A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms.

Authors:  Max R Schroeder; Scott T Chancey; Stephanie Thomas; Wan-Hsuan Kuo; Sarah W Satola; Monica M Farley; David S Stephens
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

9.  Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India.

Authors:  Balaji Veeraraghavan; Rosemol Varghese; Karnika Saigal; S Balasubramanian; P Sulochana Putli Bai; Binesh Lal Y; Ayyanraj Neeravi; Pavithra Baskar; Kavipriya Anandhan; C P Girish Kumar; Yuvraj Jayaraman; Vijaya Lakshmi Nag; Sujata Baveja; Bhavana J; Shrikrishna A Joshi; Ranganathan Iyer
Journal:  JAC Antimicrob Resist       Date:  2021-06-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.